SCHEMBL6469244

SCHEMBL6469244

COc1ccc2nc(Nc3nc(O)c4cccc(OC)c4n3)nc(C)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.48
ALDH1A1 P00352 8/20 0.48
MAPT P10636 8/20 0.48
KMT2A Q03164 6/20 0.48
MEN1 O00255 5/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 2/20 0.48
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 5/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 3/20 0.46
LMNA P02545 2/20 0.45
USP2 O75604 2/20 0.45
PTPN11 Q06124 1/20 0.45
HTT P42858 1/20 0.45
ALOX12 P18054 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470483 0.90 ALDH1A1 (0.53) TDP2ALDH1A1MAPTKMT2AMEN1
SCHEMBL6469112 0.88 JUND (0.43) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL6468620 0.87 TDP2 (0.43) TDP2ALDH1A1MAPTKMT2AMEN1
SCHEMBL6470146 0.86 MAPT (0.61) TDP2ALDH1A1MAPTKMT2AMEN1
SCHEMBL6468016 0.86 NPSR1 (0.59) TDP2ALDH1A1MAPTKMT2AMEN1
SCHEMBL6469519 0.86 TP53 (0.41) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL6465726 0.85 KMT2A (0.50) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL6469542 0.84 NPSR1 (0.55) TDP2ALDH1A1MAPTKMT2AMEN1
Trifluoroacetic Acid SCHEMBL6470467 0.83 ADORA2A (0.40) TDP2ALDH1A1MAPTKMT2AMEN1
Trifluoroacetic Acid SCHEMBL6468608 0.83 TDP2 (0.46) TDP2ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB TDP2 424/4885ALDH1A1 3154/4885MAPT 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.